EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma

Silvia Codenotti, Francesco Marampon, Francesca Megiorni, Carlo Guglielmo Cattaneo, Stefano Gastaldello, Enrico Pozzo, Maurilio Sampaolesi, Rossella Rota, Charles Keller, Alessandro Fanzani

Cancer Drug Resistance · 03.12.2025

DOI: 10.20517/cdr.2025.145 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, online erschienen am 03.12.2025. Verfasst von Silvia Codenotti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rhabdomyosarcomas (RMS) are aggressive pediatric soft tissue tumors. The fusion-negative subtype (FN-RMS) is characterized by RAS pathway mutations and genomic instability. While standard chemotherapies - vincristine, actinomycin D, and alkylating agents - are effective against localized disease, multidrug resistance (MDR) often leads to treatment failure in relapsed and metastatic RMS. Key drivers of MDR in FN-RMS include dysregulated RAS/PI3K signaling, enhanced DNA repair, evasion of apoptosis, and alterations in drug transport and metabolism. Preclinically, vertical inhibition of the RAS/MAPK and PI3K/AKT/mTOR pathways shows promise but is limited by toxicity and compensatory feedback. Combination strategies targeting MEK, IGF1R, and PI3K, as well as epigenetic regulators and metabolic pathways, demonstrate synergistic effects. BH3 mimetics can restore apoptotic sensitivity, especially in FBW7-deficient tumors. Radiotherapy resistance is mediated through the DNA-PK–mTORC2–AKT axis, while drug transporters such as ABCB1 and SLC7A11, along with age-dependent CYP enzyme expression, affect drug bioavailability. Targeting these convergent mechanisms offers a promising therapeutic strategy to overcome resistance in FN-RMS.

Schlagwörter

Stichwörter der Autor:innen

PI3KRASRhabdomyosarcomadrug resistance

Autor:innen und Institutionen

  • Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.
  • These authors equally contributed to this work.
  • Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome 00161, Italy.
  • Department of Experimental Medicine, "Sapienza" University of Rome, Rome 00161, Italy.
  • Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm 17177, Sweden.
  • Department of Development and Regeneration, KU Leuven, Leuven 3000, Belgium.

Zitieren

APA

Codenotti, S., Marampon, F., Megiorni, F., Cattaneo, C. G., Gastaldello, S., Pozzo, E., Sampaolesi, M., Rota, R., Keller, C., & Fanzani, A. (2025). Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2025.145

Vancouver

Codenotti S, Marampon F, Megiorni F, Cattaneo CG, Gastaldello S, Pozzo E, et al. Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma. Cancer Drug Resistance. 2025. doi:10.20517/cdr.2025.145

BibTeX
@article{Codenotti2025,
  author = {Codenotti, Silvia and Marampon, Francesco and Megiorni, Francesca and Cattaneo, Carlo Guglielmo and Gastaldello, Stefano and Pozzo, Enrico and Sampaolesi, Maurilio and Rota, Rossella and Keller, Charles and Fanzani, Alessandro},
  title = {Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma},
  journal = {Cancer Drug Resistance},
  year = {2025},
  doi = {10.20517/cdr.2025.145}
}
Kostenlos starten →